| |
|
|
Session 79
Poster Presentations Immune Based Therapy: IL-2 and Other Approaches Wednesday 1:30 - 3:30 pm Hall A |
| 648 | Safety and Pharmacokinetics of Subcutaneous BAY 50-4798, a Recombinant IL-2 Selective Agonist, in Cynomolgus Monkeys A. Fleser*, C.-M. L. Tseng, B. Zhao, L. Neyer, M. Boes, T. Reynolds, E. Cheung Bayer Corp, Berkeley, CA |
| 649 | Interleukin-2 in Conjunction with HAART in Early HIV Infection Increases Naïve and Memory CD4 Cells and Lowers Activation Markers F. M. Hecht, C. B. Hare*, M. S. McGrath, L. Liu, R. L. Gascon, J. O. Kahn, J. A. Levy Univ of California at San Francisco |
| 650 | Preservation of CCR5 Usage Among Primary HIV Isolates of Individuals Receiving Intermittent Interleukin-2 Plus Antiretroviral Therapy S. Ghezzi1, F. Pacciarini1, S. Nozza1, F. Veglia2, A. Lazzarin1, G. Tambussi*1, G. Poli1 1San Raffaele Sci Inst, Milan, Italy and 2Inst for Sci Informatio, Turin, Italy |
| 651 | Effect of IL-2 Therapy on T-cell Phenotype, Activation, and IL-2 Receptor Expression A. Sullivan*1, G. Hardy2, C. Burton2, A. Pires2, M. Nelson1, F. Gotch2, B. Gazzard1, N. Imami2 1Chelsea and Westminster Hosp, London, UK and 2Imperial Coll of Sci, Tech and Med, London, UK |
| 652 | Evolution of HIV-1 Proviral DNA per Millions of PBMC in Patients with Advanced HIV Disease (CD4 < 200 cells/mm3) Receiving IL-2 Combined with HAART vs HAART Alone C. Delaugerre*, K. Gourlain, R. Tubiana, G. Carcelain, A. G. Marcelin, C. Chouquet, M. Mouroux, C. Duvivier, B. Autran, D. Costagliola, C. Katlama, V. Calvez Pitié-Salpêtrière Hosp, Paris, France |
| 653 | Granulocyte Macrophage-colony Stimulating Factor Blunts Viral Rebound during Interruption of HAART C. Fagard1, H. F. Günthard2, H. H. Hirsch3, M. Egger4, P. Vernazza5, E. Bernasconi6, A. Telenti7, M. Le Braz1, L. Perrin1, B. Hirschel*1, Swiss HIV Cohort8 1Univ Hosp, Geneva, Switzerland; 2Univ Hosp, Zurich, Switzerland; 3Univ Hosp, Basel, Switzerland; 4Inselspital, Berne, Switzerland; 5Univ Hosp, St Gallen, Switzerland; 6Hosp Civico, Lugano, Switzerland; 7CHUV Lausanne, Switzerland; and 8 |
| 654 | Positive Immunomodulatory Effects of Tucaresol in HIV-infected Patients: Results from a Phase I/II Trial after 40 Weeks of Follow-up A. Bandera*1, A. Gori1, D. Trabattoni2, M. Saresella2, S. Fossati2, G. Marchetti1, J. Rhodes3, L. Meroni1, D. Thorborn3, R. Panebianco4, H. McDade3, M. Moroni1, F. Franzetti1, D. Bray3, M. Clerici2 1Inst of Infectious Diseases and Tropical Med, Univ of Milan, Italy; 2Univ of Milan, Italy; 3GlaxoSmithKline, Greenford, UK; and 4GlaxoSmithKline, Verona, Italy |
| 655 | IL-4/13 Trap: A Novel Immunomodulatory Agent for the Treatment of HIV Disease E. Furfine*, E. Koehler-Stec, S. Ramakanth, S. Murthy, C. Radziejewski, N. Stahl Regeneron Pharm, Tarrytown, NY |
| 656 | The Addition of Mycophenolate Mophetil (MMF) to HAART in Early Stage HIV-infected Patients Is Associated with a Probable Decrease in Viral Reservoir Size F. García*, M. Plana, M. Brunet, M. Arnedo, C. Gil, E. Vidal, G. Mestre, J. Martorell, J. M. Miró, J. Mallolas, J. L. Blanco, E. Martínez, T. Pumarola, T. Gallart, J. M. Gatell Inst d'Investigacions Biomèdiques August Pi i Sunyer, Hosp Clin, Univ of Barcelona, Spain |
| 657 | Normal Immune Reconstitution in Acute and Chronic HIV-1 Infected, Treatment Naïve Patients during Combined Treatment of Mycophenolate Mofetil and HAART N. Vrisekoop1,2, S. U. C. Sankatsing2,3, C. A. Jansen1,2, M. T. L. Roos1,2, S. A. Otto1,2, H. Schuitemaker1,2, J. M. A. Lange2,3, F. Miedema*1,2, J. M. Prins2,3 1Sanquin Res at CLB, Amsterdam, The Netherlands; 2Academic Med Ctr, Univ of Amsterdam, The Netherlands; and 3Intl Antiviral Therapy Eval Ctr, Amsterdam, The Netherlands |
| 658 | Patterns of Viral Rebound and CD4 Slopes in Patients with Primary HIV-1 Infection with Persistent Undetectable Viremia Treated with Supervised Treatment Interruption Plus Mycophenolate Mofetil G. Tambussi*1, G. P. Rizzardi1, A. Lazzarin1, G. Pantaleo2 1HSR Hosp San Raffaele, Milan, Italy and 2CHUV Lausanne, Switzerland |
| 658a | Mycophenolate Mofetil Does Not Have an Additional Effect on Plasma HIV-RNA Decay and on the Pool of Latently Infected Resting CD4+ T Lymphocytes in Therapy Naïve HIV-1 Patients Starting HAART S. Sankatsing*1,2, S. Jurriaans2, H. Schuitemaker3, M. Cornelissen2, L. van Weert 1, J. Lange1,2, J. Prins2 1International Antiviral Therapy Evaluation Center, Amsterdam, The Netherlands; 2Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; and 3Sanquin Research and Landsteiner Laboratory, University of Amsterdam, Amsterdam, The Netherlands |